LOGIN  |  REGISTER
Chimerix
C4 Therapeutics

Lantheus to Present at Upcoming Investor Conferences

February 21, 2025 | Last Trade: US$101.32 0.80 0.80

BEDFORD, Mass., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced members of its management team will present at the following upcoming investor conferences.

  • B. Riley Securities Precision Oncology & Radiopharma Day in New York on February 28
  • TD Cowen 45th Annual Health Care Conference in Boston on March 4 at 2:30 pm ET
  • Leerink Global Healthcare Conference 2025 in Miami on March 11 at 1:40 pm ET

A live webcast will be available for the TD Cowen 45th Annual Health Care Conference and Leerink Global Healthcare Conference presentations on the Investors section of the Company’s website at www.lantheus.com. A replay of the webcasts will be available on the Company’s website for at least 30 days following the live presentations.

About Lantheus

Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.

Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Melissa Downs
Senior Director, External Communications
646-975-2533
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page